cGP is naturally produced in the human body and plays a critical role in regulating IGF-1 function, a hormone essential for growth and development. However, as we age, the body's production of cGP declines, leading to cognitive decline and impaired energy metabolism.
Low endogenous levels of cGP have also been linked to the development of conditions such as diabetes and dementia.
Dr. Guan's recent clinical studies demonstrate that cGP supplementation can significantly improve vascular complications in type-2 diabetes, including peripheral neuropathy and diabetic nephropathy.
This groundbreaking research presents an opportunity to develop targeted medicated food products aimed at enhancing the quality of life and clinical outcomes for the 230 million diabetic patients worldwide who are suffering from peripheral neuropathy.